Suppr超能文献

血清miR-200c和miR-371-5p作为川崎病有用的诊断生物标志物和治疗靶点

Serum miR-200c and miR-371-5p as the Useful Diagnostic Biomarkers and Therapeutic Targets in Kawasaki Disease.

作者信息

Zhang Wei, Wang Yan, Zeng Yiwen, Hu Liyi, Zou Guotao

机构信息

Department of Pediatrics, The Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China.

Department of Laboratory Medicine, The Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China.

出版信息

Biomed Res Int. 2017;2017:8257862. doi: 10.1155/2017/8257862. Epub 2017 Jun 1.

Abstract

Kawasaki disease (KD) has complexly clinical features and laboratory parameters and there is no definitive biomarker for this disease and the therapy of KD also is complex and uncertain. In this study, 102 KD patients and 80 healthy controls were enrolled in this study and the serum microRNAs were detected by qRT-PCR. The results showed that, compared with KD patients with a good response to high-dose intravenous immunoglobulin (IVIG) therapy, serum miR-200c and miR-371-5p were significantly higher in KD patients with no response to IVIG therapy; compared with KD patients not needing plasma exchange, these two microRNAs were also significantly higher in KD patients needing plasma exchange. In addition, combination of serum miR-200c and miR-371-5p reflected obvious separation between KD patients and healthy controls or between KD patients with no response to IVIG therapy and KD patients with good response to IVIG therapy or KD patients needing plasma exchange and KD patients not needing plasma exchange. Finally, both serum miR-200c and miR-371-5p were also significantly lower in KD under different kinds of therapy. Therefore, serum miR-200c and miR-371-5p have ability as the useful diagnostic biomarkers and therapeutic targets in Kawasaki disease.

摘要

川崎病(KD)具有复杂的临床特征和实验室参数,且该疾病没有明确的生物标志物,KD的治疗也复杂且不确定。在本研究中,纳入了102例KD患者和80例健康对照,通过qRT-PCR检测血清微小RNA。结果显示,与对大剂量静脉注射免疫球蛋白(IVIG)治疗反应良好的KD患者相比,对IVIG治疗无反应的KD患者血清miR-200c和miR-371-5p显著更高;与不需要血浆置换的KD患者相比,需要血浆置换的KD患者这两种微小RNA也显著更高。此外,血清miR-200c和miR-371-5p的联合反映了KD患者与健康对照之间,或对IVIG治疗无反应的KD患者与对IVIG治疗反应良好的KD患者之间,或需要血浆置换的KD患者与不需要血浆置换的KD患者之间有明显区分。最后,在不同治疗方式下KD患者的血清miR-200c和miR-371-5p也均显著降低。因此,血清miR-200c和miR-371-5p有能力作为川崎病有用的诊断生物标志物和治疗靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验